BENJAMIN BROWN, Executive Director, American Society of Pharmacovigilance

•   A driven entrepreneur; relentless, innovative, passionate and always focused on results Benjamin Brown is Co-Founder and Executive Director of the American Society of Pharmacovigilance, a member-based organization redefining how America thinks about adverse drug events. In his role, he sets the organization’s vision, oversees the strategic direction of the Society, supports its leaders and forges cross-sector partnerships, collaborations and coalitions uniting key stakeholders to address shared-challenges and advance the promise of precision medicine. In 2020,he co-created and founded the Standardizing Laboratory Practices in Pharmacogenomics Initiative (STRIPE), which is the nation’s first and only Collaborative Community for Pharmacogenomics, recognized and supported by the FDA’s Center for Devices and Radiological Health and Center for Drug Evaluation and Research.Additionally, he is actively involved in pharmacogenomics at the National Institute of Health’s, National Human Genome Research Institute, serving as member on the PGX working group (ISCC-PEG) to improve genomic literacy of healthcare providers and enhance the effective practice of clinical genomic medicine by facilitating interactions among the key stakeholders in genomics education.

•   He is very active in the precision medicine community, and currently co-chairs the Pharmacogenomics, Access and Reimbursement Coalition, a global gathering of precision medicine focused professionals creating new ways of thinking at the intersection of health economics, precision medicine and value-based care.

•   His unique, rich professional background spans from his start in investment banking, portfolio management, and sales working as a financial professional at the world's top investment banks where he focused on providing asset and risk management solutions for families, business owners, and foundations that control significant pools of wealth and liquidity.